Exhibit 10.1

 

AMENDMENT AGREEMENT

 

to the Collaboration and License Agreement, dated February 2, 2011 and the
Supply Agreement, dated February 2, 2011

 

by and between

 

OPTIMER PHARMACEUTICALS, INC.

10110 Sorrento Valley Rd., Suite C

San Diego, California 92121

(hereinafter referred to as “Optimer”),

 

and

 

ASTELLAS PHARMA EUROPE LTD.

Lovett House, Lovett Road, Staines, Middlesex

TW18 3AZ, United Kingdom

(hereinafter referred to as “Partner”),

 

Optimer and Partner are hereinafter also referred to as the “Parties”.

 

WITNESSETH:

 

WHEREAS, Optimer and Partner executed a Collaboration and License Agreement,  
dated February 2, 2011, for Products (as defined therein) (hereinafter referred
to as the “Collaboration and License Agreement”) and also a Supply Agreement,
dated February 2, 2011, for Product (as defined therein) (hereinafter referred
to as the “Supply Agreement”) (for the purpose of this Amendment Agreement, the
Collaboration and License Agreement and the Supply Agreement are referred to
together as the “Agreements”); and

 

WHEREAS, Optimer and Partner wish to amend certain terms and conditions set out
in the Agreements;

 

NOW, THEREFORE, in consideration of the premises and the mutual agreements and
covenants set forth herein, the Parties have agreed as follows:

 

1.     Definition

 

1.1 Unless otherwise provided, capitalized terms shall have the meanings
ascribed to them in the Agreements.

 

2.     Change in Territory

 

2.1 “Albania”, “Bosnia-Herzegovina”, “Croatia”, “Macedonia”, “Montenegro”,
“Serbia (including Kosovo)”, “Georgia”, “Mongolia” and “all additional
territories in Africa”

 

--------------------------------------------------------------------------------

 

shall be added to the Territory, and the definition of the Territory as set out
in Section 1.103 of the Collaboration and License Agreement shall be revised
accordingly.

 

2.2. “Albania”, “Bosnia-Herzegovina”, “Croatia”, “Macedonia”, “Montenegro”,
“Serbia (including Kosovo)”, “Georgia”, “Mongolia” and “all additional
territories in Africa” shall be added to the Territory, and the definition of
Territory as set out in Section 1.61 of the Supply Agreement shall be revised
accordingly.

 

2.3  For the sake of clarity, the Territory, as revised hereunder, shall
correspond to the countries listed below:

 

“Albania, Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,
Republic of Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta,
Macedonia, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Serbia
(including Kosovo), Slovakia, Slovenia, Spain, Sweden, Switzerland, United
Kingdom, Turkey, South Africa, Russia, Armenia, Azerbaijan, Belarus, Georgia,
Kazakhstan, Kyrgyzstan, Moldova, Mongolia. Tajikistan, Turkmenistan, Ukraine,
Uzbekistan, Middle East (Bahrain, Gaza Strip, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates, West
Bank (Palestine) and Yemen), North Africa (Algeria, Egypt, Libya, Morocco and
Tunisia) and all additional territories in Africa”

 

3.     Other

 

3.1 Except as specifically provided herein, the Agreements shall remain
unchanged and in full force and effect without amendment or modification.

 

[The next page is the signature page]

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the Parties have caused this instrument to be executed by
their duly authorised representatives.

 

 

OPTIMER PHARMACEUTICALS, INC.

 

ASTELLAS PHARMA EUROPE LTD

 

 

 

By:

/s/ Kurt Hartman

 

By:

/s/ Jenny Temko

 

 

 

 

 

Name:

Kurt Hartman

 

Name:

/s/ Jenny Temko

 

 

 

 

 

Title:

General Counsel and SVP

 

Title:

SVP and General Counsel

 

 

 

 

 

Date:

3/17/11

 

Date:

29/03/11

 

--------------------------------------------------------------------------------